Thursday's Small-Cap Winners & Losers
Small-cap stocks clung to the lower reaches of the broader market Thursday, largely moving in sync with the lukewarm Dow Jones Industrial Average.
Weighing things down were several health stocks, among them Progen Pharmaceuticals (PGLA), an Australia-based biotech that agreed to sell 6.9 million of its shares to institutional and other investors for a heavily discounted price of $4.75 apiece. Shares were plunging 19.9% to $4.83 in recent trading.
Monogram Biosciences (MGRM) lost a penny more than the Street had expected, according to Thomson Financial, and came in under sales estimates. Shares of the diagnostic-substances maker lost 11.4% to $1.64.
Fellow Californian Clarient (CLRT), purveyor of cancer-related diagnostic services, sank 13.2% to $2.10 after posting a first-quarter continuing-operations loss of 6 cents a share that missed two analysts' estimates by 2 cents.
Meanwhile, medical-products maker Thoratec (THOR), of Pleasanton, Calif., plunged 14.5% to $17.01 despite edging out top- and bottom-line estimates for the first quarter. Town Sports International (CLUB), a New York-based fitness-club operator, was off 9.4% to $20.54 after widening its GAAP-based first-quarter loss. Small tech losers included semiconductor-equipment maker Axcelis Technologies (ACLS), which reported first-quarter income that fell just under the Street's 4-cent-per-share targets, and Optelecom-NKF (OPTC), a communications-equipment maker that swung to a first-quarter loss vs. last year. Axcelis, based in Beverly, Mass., plummeted 19.2% to $6.63. Maryland-based Optelecom tumbled 19.8% to $6.71.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV